Hydromorphone

also known as Dilaudid · Hydromorphone Hydrochloride · OROS hydromorphone · Hydromorphone HCI · Hydromorphone HCl · OROS hydromorphone HCI (slow release) · OROS hydromorphone HCL · Dilaudid CR · +32 more

Other / unclassified targets OPRM1 via activation

Developed for: chronic pain syndrome · neuropathy, painful · osteoarthritis, knee · cancer · osteoarthritis, hip · acute coronary syndrome · hematopoietic and lymphoid cell neoplasm · heroin dependence
+6 more
· mucositis · musculoskeletal system disorder · pregnancy disorder · sickle cell disease · cancer of unknown primary site · migraine disorder
Investigated by: Alza Corporation · Montefiore Medical Center · National Institute on Drug Abuse (NIDA) · Johns Hopkins University · Mallinckrodt · Mayo Clinic
+86 more
· Fujian Cancer Hospital · Janssen Korea, Ltd., Korea · M.D. Anderson Cancer Center · Emory University · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Maternal and Child Health Hospital of Hubei Province · Mount Sinai Hospital, Canada · National Cancer Institute (NCI) · Patient-Centered Outcomes Research Institute · Piramal Critical Care, Ltd. · Purdue Pharma LP · Second Hospital of Jilin University · University of Alberta · University of British Columbia · University of Chicago · University of Michigan · Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Albert Einstein College of Medicine · Allina Health System · Archimedes Pharma US, Inc. · Beth Israel Deaconess Medical Center · Brigham and Women's Hospital · Canadian Institutes of Health Research (CIHR) · Cape Fear Valley Health System · Children's Mercy Hospital Kansas City · Columbia University · Duke University · Erasmus Medical Center · First Affiliated Hospital, Sun Yat-Sen University · Grace Shih, MD · Grünenthal GmbH · Gyeongsang National University Hospital · Hamilton Health Sciences Corporation · Hordinsky, Maria K., MD · Icahn School of Medicine at Mount Sinai · Indivior Inc. · Innerchange Charitable Society · Janssen Pharmaceutica · Janssen Pharmaceutica N.V., Belgium · Janssen Research & Development, LLC · Janssen-Cilag International NV · Jinshazhou Hospital of Guangzhou University of Chinese Medicine · Johnson & Johnson Taiwan Ltd · Jun Wang · Liquan Liang · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Masimo Corporation · McMaster University · Mundipharma Research GmbH & Co KG · Nanfang Hospital, Southern Medical University · National Heart, Lung, and Blood Institute (NHLBI) · Northwestern University · Nova Scotia Health Authority · OrthoCarolina Research Institute, Inc. · Parc de Salut Mar · Peking University People's Hospital · Providence Healthcare · Qianfoshan Hospital · Qinghai Red Cross Hospital · Roswell Park Cancer Institute · Second Affiliated Hospital, School of Medicine, Zhejiang University · St. Louis Children's Hospital · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · The Hospital for Sick Children · The Physicians' Services Incorporated Foundation · Thomas Jefferson University · TriHealth Inc. · Universidad Europea de Canarias · University Health Network, Toronto · University of Calgary · University of California, San Francisco · University of Manitoba · University of Montreal Hospital Centre (CHUM) · University of North Carolina, Chapel Hill · all 92 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	DILAUDID-HP	—	2009-04-30	fda.gov ↗
Approved	US (FDA)	DILAUDID-HP	—	1984-01-11	fda.gov ↗

Trials 122 · started per year

today

US approved 1984

1983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT07489625	Mar 2026 → Dec 2027 expected	—	Qinghai Red Cross Hospital	Not yet recruiting	No outcome recorded
Phase 0	NCT05610072	Dec 2022 → Mar 2026	substance-related disorder	William Stoops	Completed	No outcome recorded
Phase 0	NCT01866254	May 2013 → Dec 2017	—	Grace Shih, MD	Completed	No outcome recorded
Phase 112 trials
Phase 1	NCT04081376	Nov → Dec 2019	—	Parc de Salut Mar	Completed	No outcome recorded
Phase 1	NCT03933865	Oct 2018 → Feb 2022	opiate dependence	University of California, San Francisco	Terminated	No outcome recorded
Phase 1	NCT02787928	Apr 2016 → Dec 2017	—	Virginia Commonwealth University	Terminated	No outcome recorded
Phase 1	NCT01642030	Aug 2013 → Jul 2017	opiate dependence	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT01824524	Dec 2011 → Aug 2012	—	Xian-Janssen Pharmaceutical Ltd.	Completed	No outcome recorded
Phase 1	NCT01487564	Oct 2011 → Jan 2012	—	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT01487512	Mar → Jul 2011	—	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 1	NCT03768024	Jun → Oct 2007	—	Grünenthal GmbH	Completed	No outcome recorded
Phase 1	NCT00853554	Dec 2002	—	Mallinckrodt	Completed	No outcome recorded
Phase 1	NCT00410878	? → Aug 1999	—	Alza Corporation	Completed	No outcome recorded
Phase 1	NCT00398957	? → Sep 1998	—	Alza Corporation	Completed	No outcome recorded
Phase 1	NCT00399295	? → Jun 1997	—	Alza Corporation	Completed	No outcome recorded

Phase 1/23 trials
Phase 1/2	NCT07672301	Mar 2026 → Jun 2027 expected	—	University of Chicago	Recruiting	No outcome recorded
Phase 1/2	NCT06949059	Jan 2025 → Dec 2026 expected	acute coronary syndrome	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Recruiting	No outcome recorded
Phase 1/2	NCT00177060	Oct 2003 → May 2007	—	Hordinsky, Maria K., MD	Terminated	No outcome recorded
Phase 221 trials
Phase 2	NCT07224620	Nov 2025 → May 2026	—	Beth Israel Deaconess Medical Center	Completed	No outcome recorded
Phase 2	NCT06036797	Sep → Oct 2023	—	Maternal and Child Health Hospital of Hubei Province	Unknown	No outcome recorded
Phase 2	NCT05579223	Oct 2022 → Jan 2024	anus disorder	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
Phase 2	NCT05901441	Jun 2022 → May 2023	—	Maternal and Child Health Hospital of Hubei Province	Completed	No outcome recorded
Phase 2	NCT05565495	Jan 2022 → Sep 2024 overdue	—	Xiaobo Yang, MD	Recruiting	No outcome recorded
Phase 2	NCT04243954	Apr → Oct 2020	—	Fujian Cancer Hospital	Completed	No outcome recorded
Phase 2	NCT04036968	Feb 2020 → Nov 2022	substance-related disorder	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT03767933	Apr 2019 → Mar 2023	musculoskeletal system disorder	University of Alberta	Completed	No outcome recorded
Phase 2	NCT03098563	Nov 2017 → Nov 2023	osteoarthritis, knee	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT02901275	Dec 2016 → Mar 2020	—	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT02437669	May 2015 → Apr 2018	—	Columbia University	Completed	No outcome recorded
Phase 2	NCT02360371	Apr 2015 → May 2020	opioid abuse	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT02096003	May 2014 → May 2017	—	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 2	NCT02044094	Nov 2013 → Jul 2014	substance-related disorder	Indivior Inc.	Completed	No outcome recorded
Phase 2	NCT01598506	Sep 2013 → Feb 2014	—	Emory University	Completed	No outcome recorded
Phase 2	NCT01598545	Feb 2013 → Jun 2014	—	Emory University	Completed	No outcome recorded
Phase 2	NCT01675778	Oct 2011 → Oct 2012	—	Albert Einstein College of Medicine	Completed	No outcome recorded
Phase 2	NCT00305110	Jan → Oct 2006	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 2	NCT00195910	Oct 2004 → Jan 2005	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 2	NCT00411307	? → Oct 2001	—	Alza Corporation	Completed	No outcome recorded
Phase 2	NCT00398788	? → Nov 2001	—	Alza Corporation	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT00992576	Jan 2010 → Nov 2011	constipation disorder	Mundipharma Research GmbH & Co KG	Completed	No outcome recorded
Phase 2/3	NCT00305058	Jul 2005 → Mar 2007	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 333 trials
Phase 3	NCT04785768	Jul 2021 → May 2024	—	Fujian Cancer Hospital	Completed	No outcome recorded
Phase 3	NCT03933397	Aug 2019 → May 2022	sickle cell disease	Duke University	Terminated	No outcome recorded
Phase 3	NCT03375515	Sep 2018 → Dec 2019	—	Fujian Cancer Hospital	Completed	No outcome recorded
Phase 3	NCT05576675	May 2018 → Mar 2022	—	Xijing Hospital	Completed	No outcome recorded
Phase 3	NCT03214510	Oct 2017 → Jul 2027 expected	hepatobiliary disorder	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 3	NCT02321319	Mar 2017 → Feb 2019	chronic pain syndrome	Mallinckrodt	Terminated	No outcome recorded
Phase 3	NCT02423876	Mar 2015 → Jan 2022	female reproductive organ cancer	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 3	NCT02084355	Apr 2014 → Dec 2015	cancer	Gyeongsang National University Hospital	Unknown	No outcome recorded
Phase 3	NCT01709747	Jun 2013 → Feb 2018	chronic pain syndrome	Piramal Critical Care, Ltd.	Completed	No outcome recorded
Phase 3	NCT01709721	Feb 2013 → Feb 2018	chronic pain syndrome	Piramal Critical Care, Ltd.	Completed	No outcome recorded
Phase 3	NCT01447212	Dec 2011 → Jun 2014	heroin dependence	University of British Columbia	Completed	No outcome recorded
Phase 3	NCT01311895	Jan → Nov 2011	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 3	NCT01205126	Dec 2009 → Feb 2011	—	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00474110	Aug 2009 → Dec 2011	mucositis	University of British Columbia	Withdrawn	No outcome recorded
Phase 3	NCT00803283	Nov → Dec 2008	—	Johnson & Johnson Taiwan Ltd	Terminated	No outcome recorded
Phase 3	NCT00825370	Oct 2008 → May 2009	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 3	NCT00631319	Feb 2008 → Apr 2009	chronic pain syndrome	Mallinckrodt	Completed	No outcome recorded
Phase 3	NCT00627367	Dec 2007 → Mar 2008	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 3	NCT00980798	Oct 2007 → Nov 2008	osteoarthritis, hip, osteoarthritis, knee	Janssen-Cilag International NV	Completed	No outcome recorded
Phase 3	NCT00549042	Oct 2007 → Jan 2009	chronic pain syndrome	Mallinckrodt	Completed	No outcome recorded
Phase 3	NCT00261495	Mar 2006 → Apr 2008	—	Janssen Pharmaceutica N.V., Belgium	Completed	No outcome recorded
Phase 3	NCT00125801	Aug 2005 → May 2008	neoplasm	Erasmus Medical Center	Terminated	No outcome recorded
Phase 3	NCT00365898	Jul 2005	chronic pain syndrome	Purdue Pharma LP	Terminated	No outcome recorded
Phase 3	NCT00411164	Nov 2003 → May 2005	osteoarthritis, hip, osteoarthritis, knee	Alza Corporation	Completed	No outcome recorded
Phase 3	NCT00003115	Jun 1996 → Jan 2003	prostate cancer	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 3	NCT00411268	? → Jun 2001	—	Alza Corporation	Completed	No outcome recorded
Phase 3	NCT00410748	? → Jun 2000	—	Alza Corporation	Completed	No outcome recorded
Phase 3	NCT00411034	? → Sep 1999	—	Alza Corporation	Completed	No outcome recorded
Phase 3	NCT00410644	? → Feb 1999	—	Alza Corporation	Completed	No outcome recorded
Phase 3	NCT00410540	? → May 2001	—	Alza Corporation	Completed	No outcome recorded
Phase 3	NCT00410787	? → Apr 2002	—	Alza Corporation	Completed	No outcome recorded
Phase 3	NCT00410943	? → Jun 1999	—	Alza Corporation	Completed	No outcome recorded
Phase 3	NCT00399048	? → May 2001	osteoarthritis, hip, osteoarthritis, knee	Alza Corporation	Completed	No outcome recorded

Phase 431 trials
Phase 4	NCT06784180	Feb 2026 → Jan 2029	opiate dependence	University of North Carolina, Chapel Hill	Withdrawn	No outcome recorded
Phase 4	NCT06823180	Mar → Aug 2025	—	Liquan Liang	Completed	No outcome recorded
Phase 4	NCT06671002	Jan 2025 → Oct 2026 expected	—	University of Michigan	Recruiting	No outcome recorded
Phase 4	NCT06669650	Sep 2024 → Dec 2025 overdue	opiate dependence	University of Tennessee Graduate School of Medicine	Active not recruiting	No outcome recorded
Phase 4	NCT06525740	Sep 2024 → Sep 2029 expected	female reproductive organ cancer	Mayo Clinic	Recruiting	No outcome recorded
Phase 4	NCT06495632	Aug 2024 → Jul 2026 overdue	—	Cape Fear Valley Health System	Recruiting	No outcome recorded
Phase 4	NCT07315022	Aug 2024 → Aug 2025	—	First Affiliated Hospital, Sun Yat-Sen University	Completed	No outcome recorded
Phase 4	NCT05848635	May 2023 → May 2024	pulmonary coin lesion	Qianfoshan Hospital	Unknown	No outcome recorded
Phase 4	NCT05708521	Apr 2023 → May 2024 overdue	neuropathy, painful, substance-related disorder	Nova Scotia Health Authority	Active not recruiting	No outcome recorded
Phase 4	NCT05552443	Mar 2023 → Oct 2024	—	Mayo Clinic	Terminated	No outcome recorded
Phase 4	NCT05722002	Feb 2023 → Dec 2026 expected	neuropathy, painful	University of Michigan	Recruiting	No outcome recorded
Phase 4	NCT04752033	Mar 2021 → Feb 2023	—	Mayo Clinic	Completed	No outcome recorded
Phase 4	NCT03592992	Nov 2020 → Jul 2022	—	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Completed	No outcome recorded
Phase 4	NCT04296305	Sep 2020 → Dec 2027 expected	cancer, hematopoietic and lymphoid cell neoplasm	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 4	NCT04436224	Sep 2020 → Jun 2022	—	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
Phase 4	NCT04258631	Jul 2020 → Aug 2023	female reproductive system neoplasm	Mayo Clinic	Completed	No outcome recorded
Phase 4	NCT04396587	May 2020 → Jan 2023	substance-related disorder	Peking University People's Hospital	Completed	No outcome recorded
Phase 4	NCT04111328	Oct 2019 → Sep 2020	—	Jun Wang	Completed	No outcome recorded
Phase 4	NCT03648008	May → Sep 2018	neuropathy, painful	Second Affiliated Hospital, School of Medicine, Zhejiang University	Completed	No outcome recorded
Phase 4	NCT02939209	Apr 2017 → May 2022	rotator cuff syndrome	Vishal Uppal	Completed	No outcome recorded
Phase 4	NCT01812759	Jan → Oct 2014	pain agnosia	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 4	NCT02067520	Jan → Dec 2014	—	Thomas Jefferson University	Completed	No outcome recorded
Phase 4	NCT01892709	Jun 2013 → Apr 2014	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 4	NCT01621100	Dec 2011 → Sep 2012	—	Janssen Korea, Ltd., Korea	Completed	No outcome recorded
Phase 4	NCT01648699	Apr → Sep 2010	—	Janssen Pharmaceutica	Terminated	No outcome recorded
Phase 4	NCT01429298	Mar → Nov 2010	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 4	NCT01429285	Jul 2009 → Jun 2012	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 4	NCT00766831	Oct 2008 → Jun 2010	—	Janssen Korea, Ltd., Korea	Completed	No outcome recorded
Phase 4	NCT01006356	Oct 2008 → Aug 2009	cancer	Janssen Korea, Ltd., Korea	Completed	No outcome recorded
Phase 4	NCT00682435	Aug → Nov 2007	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 4	NCT00465647	Apr 2007 → May 2009	—	Purdue Pharma LP	Completed	No outcome recorded

Phase not applicable17 trials
—	NCT06240390	May → Aug 2024	neuropathy, painful	Universidad Europea de Canarias	Withdrawn	No outcome recorded
—	NCT06218160	Nov 2022 → Nov 2023	—	Second Hospital of Jilin University	Completed	No outcome recorded
—	NCT06205199	Oct 2022 → Nov 2023	—	Second Hospital of Jilin University	Completed	No outcome recorded
—	NCT05375916	May 2022 → Nov 2023	substance-related disorder	University of Alberta	Completed	No outcome recorded
—	NCT04566250	Feb 2021 → Apr 2022	—	McMaster University	Completed	No outcome recorded
—	NCT04044820	Mar 2019 → Dec 2026 expected	substance-related disorder	University Health Network, Toronto	Recruiting	No outcome recorded
—	NCT04176783	Mar 2018 → Jul 2021	—	OrthoCarolina Research Institute, Inc.	Completed	No outcome recorded
—	NCT03478423	Feb 2018 → Sep 2019	—	Mount Sinai Hospital, Canada	Terminated	No outcome recorded
—	NCT02880800	Aug 2016 → Aug 2017	neuropathy, painful	Mount Sinai Hospital, Canada	Unknown	No outcome recorded
—	NCT02789969	Apr 2016 → Mar 2017	—	St. Louis Children's Hospital	Unknown	No outcome recorded
—	NCT02277782	Sep 2015 → Dec 2019	pregnancy disorder	Brigham and Women's Hospital	Terminated	No outcome recorded
—	NCT02205983	Jan 2015 → Jul 2016	—	University of Chicago	Completed	No outcome recorded
—	NCT01123486	Jan 2015	respiratory underresponsiveness to hypoxia and hypercapnia	Northwestern University	Withdrawn	No outcome recorded
—	NCT01447888	Sep 2011 → Mar 2014	—	Allina Health System	Completed	No outcome recorded
—	NCT01442818	Sep 2010 → Sep 2011	—	TriHealth Inc.	Completed	No outcome recorded
—	NCT00413582	Oct 2006 → May 2010	—	Children's Mercy Hospital Kansas City	Completed	No outcome recorded
—	NCT00158236	Jan 1997 → Mar 1998	opioid abuse	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded

Also used as a comparator or background therapy in 119 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT06617949 Comparator	Jan 2025 → Dec 2027 expected	substance-related disorder	Medical College of Wisconsin	Recruiting	No outcome recorded
Phase 0	NCT04230681 Comparator	Feb 2020 → Apr 2022	obstructive sleep apnea syndrome, tonsillitis	Washington University School of Medicine	Completed	No outcome recorded
Phase 0	NCT03579446 Background	Nov 2018 → Jun 2023	hematopoietic and lymphoid cell neoplasm, metastatic malignant neoplasm	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 0	NCT03088306 Comparator	Jul 2017 → May 2018	lumbar disk degenerative disorder, lumbar spinal stenosis	Johns Hopkins University	Completed	No outcome recorded
Phase 13 trials
Phase 1	NCT06406400 Background	May → Jul 2024	opiate dependence	AstraZeneca	Terminated	No outcome recorded
Phase 1	NCT02372591 Comparator	Aug 2015 → Jun 2017	chronic pain syndrome, opiate dependence	Johns Hopkins University	Completed	No outcome recorded
Phase 1	NCT03757559 Comparator	Apr 2013 → Mar 2014	substance abuse	Tris Pharma, Inc.	Completed	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT07430345 Comparator	May → Dec 2026 expected	—	The Cooper Health System	Recruiting	No outcome recorded
Phase 1/2	NCT00499746 Comparator	Nov 2007 → Apr 2010	opiate dependence, opioid abuse	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 216 trials
Phase 2	NCT07588802 Comparator	Jul 2026 → Apr 2027 expected	—	Massachusetts General Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT06411795 Background	Nov 2023 → Jan 2027 expected	pancreatic neoplasm, tumor of duodenum	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT05842044 Background	Sep 2023 → Sep 2026 expected	renal carcinoma	University of Miami	Recruiting	No outcome recorded
Phase 2	NCT05244226 Comparator	Apr 2022 → May 2023	obstructive sleep apnea syndrome, tonsillitis	Duke University	Completed	No outcome recorded
Phase 2	NCT04291599 Comparator	Mar 2022 → Jul 2025	acute pancreatitis	Boston Children's Hospital	Terminated	No outcome recorded
Phase 2	NCT05027919 Background	Dec 2021 → Nov 2026 expected	opiate dependence, substance withdrawal syndrome	University of Maryland, Baltimore	Recruiting	No outcome recorded
Phase 2	NCT04234191 Background	Aug 2021 → Jan 2025	opiate dependence	University of British Columbia	Unknown	No outcome recorded
Phase 2	NCT03564548 Comparator	May 2021 → Mar 2022	cancer	Tetra Bio-Pharma	Unknown	No outcome recorded
Phase 2	NCT04221165 Comparator	Aug 2020 → Sep 2023	head and neck cancer, mucositis	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Completed	No outcome recorded
Phase 2	NCT03789318 Comparator	Dec 2018 → May 2019	—	Concentric Analgesics	Completed	No outcome recorded
Phase 2	NCT03521102 Comparator	Aug 2018 → Oct 2021	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 2	NCT03448068 Background	Apr 2018 → Jan 2020	—	Mayo Clinic	Completed	No outcome recorded
Phase 2	NCT03393117 Background	Mar 2018 → Jul 2020	breast cancer	Case Comprehensive Cancer Center	Withdrawn	No outcome recorded
Phase 2	NCT03389750 Comparator	Mar 2018 → Jun 2022	substance-related disorder	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT01932554 Background	Nov 2013 → Mar 2015	sickle cell disease	St. Louis University	Withdrawn	No outcome recorded
Phase 2	NCT01218984 Background	Mar 2002 → May 2003	opiate dependence	Alkermes, Inc.	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT06559969 Comparator	Sep 2024 → Dec 2026 expected	—	University of Iowa	Recruiting	No outcome recorded
Phase 2/3	NCT05693675 Background	Oct 2023 → Jul 2024	—	The University of Texas Health Science Center, Houston	Withdrawn	No outcome recorded
Phase 2/3	NCT06785571 Comparator	Aug 2023 → Oct 2025 overdue	respiratory failure	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Recruiting	No outcome recorded
Phase 312 trials
Phase 3	NCT06940570 Comparator	Jan 2028 → Aug 2029	aplastic anemia, bone marrow failure syndrome, leukemia, severe combined immunodeficiency	University of Texas Southwestern Medical Center	Suspended	No outcome recorded
Phase 3	NCT07565870 Comparator	Jul → Dec 2026 expected	—	Alexandre P. Joosten	Not yet recruiting	No outcome recorded
Phase 3	NCT04429022 Background	Nov 2020 → May 2022	—	State University of New York at Buffalo	Completed	No outcome recorded
Phase 3	NCT04300231 Comparator	Oct 2019 → Dec 2021	—	Indiana University	Completed	No outcome recorded
Phase 3	NCT03553498 Background	Nov 2018 → May 2019	—	Albert Einstein College of Medicine	Completed	No outcome recorded
Phase 3	NCT03330119 Comparator	Oct 2017 → Jun 2018	pregnancy disorder, substance-related disorder	Brest, Norman A., M.D.	Terminated	No outcome recorded
Phase 3	NCT03151434 Comparator	Feb 2017 → Jul 2018	—	Indiana University	Completed	No outcome recorded
Phase 3	NCT02601027 Background	Nov 2015 → Sep 2019	female breast carcinoma	Stanford University	Completed	No outcome recorded
Phase 3	NCT02062879 Comparator	Apr 2014 → Jun 2016	—	University of Cincinnati	Terminated	No outcome recorded
Phase 3	NCT01986946 Background	Oct 2013 → Sep 2015	pain agnosia	Duke University	Terminated	No outcome recorded
Phase 3	NCT00822614 Comparator	Dec 2008 → Dec 2009	—	Akela Pharma, Inc.	Unknown	No outcome recorded
Phase 3	NCT00600158 Comparator	Apr 2005 → Jul 2006	ileus	University of Virginia	Completed	No outcome recorded

Phase 455 trials
Phase 4	NCT06868589 Comparator	Jun 2025 → Jul 2026 overdue	—	Lahey Clinic	Active not recruiting	No outcome recorded
Phase 4	NCT06962306 Comparator	Jun 2025 → Jun 2027 expected	cleft palate	Duke University	Recruiting	No outcome recorded
Phase 4	NCT06576830 Comparator	Nov 2024 → Dec 2028 expected	sleep apnea syndrome, tonsillitis	Duke University	Recruiting	No outcome recorded
Phase 4	NCT06575699 Comparator	Oct 2024 → Nov 2025	—	Duke University	Completed	No outcome recorded
Phase 4	NCT06429657 Background	Sep 2024 → Jan 2027	intracerebral hemorrhage, intracranial hypertension, traumatic brain injury	Henry M. Jackson Foundation for the Advancement of Military Medicine	Suspended	No outcome recorded
Phase 4	NCT06320041 Comparator	Aug 2024 → Dec 2026 expected	—	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	Recruiting	No outcome recorded
Phase 4	NCT06110546 Comparator	Feb 2024	—	The University of Texas Health Science Center, Houston	Terminated	No outcome recorded
Phase 4	NCT05231460 Comparator	Feb 2022 → Jun 2026 overdue	neuropathy, painful	University of Arizona	Enrolling by invitation	No outcome recorded
Phase 4	NCT04398316 Comparator	Feb → Jun 2021	urinary tract obstruction	Hennepin Healthcare Research Institute	Terminated	No outcome recorded
Phase 4	NCT04240626 Background	Jan 2021 → Jun 2026 overdue	morbid obesity	University of California, Davis	Active not recruiting	No outcome recorded
Phase 4	NCT03987022 Background	Aug 2019 → Apr 2022	—	MetroHealth Medical Center	Completed	No outcome recorded
Phase 4	NCT03282669 Comparator	Aug 2019 → Dec 2021	neuropathy, painful, obesity disorder, respiratory failure	Northwestern University	Withdrawn	No outcome recorded
Phase 4	NCT03972397 Background	Jul 2019 → Sep 2022	—	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT04132011 Comparator	May 2019 → Mar 2020	chronic pain syndrome	University Health Network, Toronto	Withdrawn	No outcome recorded
Phase 4	NCT03760809 Background	Jan → Feb 2019	acute stress disorder	Eye & ENT Hospital of Fudan University	Completed	No outcome recorded
Phase 4	NCT03726268 Comparator	Nov 2018 → Jul 2023	substance-related disorder	Duke University	Completed	No outcome recorded
Phase 4	NCT03619785 Comparator	Nov 2018 → Aug 2019	myopathy, congenital, with respiratory insufficiency and bone fractures	Andrew A Herring	Unknown	No outcome recorded
Phase 4	NCT03893734 Comparator	May 2018 → Aug 2020 overdue	long QT syndrome	Endeavor Health	Recruiting	No outcome recorded
Phase 4	NCT03472469 Comparator	Apr 2018 → Jul 2019	—	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT03300674 Comparator	Jan → Aug 2018	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 4	NCT03541759 Comparator	Jan → May 2018	—	AUVA Traumazentrum Vienna Site UKH Meidling	Completed	No outcome recorded
Phase 4	NCT03309163 Comparator	Oct 2017 → Jun 2019	—	Xinqiao Hospital of Chongqing	Completed	No outcome recorded
Phase 4	NCT03107481 Comparator	Jun → Nov 2017	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 4	NCT03115151 Comparator	May 2017 → Aug 2022	—	University of Texas Southwestern Medical Center	Terminated	No outcome recorded
Phase 4	NCT03052816 Background	Apr 2017 → Jun 2018	pelvic organ prolapse	University Hospitals Cleveland Medical Center	Completed	No outcome recorded
Phase 4	NCT02987920 Background	Jan 2017 → Jan 2018	—	University of Southern California	Terminated	No outcome recorded
Phase 4	NCT02958566 Comparator	Jan → Dec 2017	colon carcinoma, constipation disorder, diverticulitis of colon, paralytic ileus +1	University of Illinois College of Medicine at Peoria	Unknown	No outcome recorded
Phase 4	NCT03104816 Background	Oct 2016 → Oct 2017	—	University of Southern California	Terminated	No outcome recorded
Phase 4	NCT02785003 Background	Jul 2016 → Aug 2017	neuropathy, painful	Medical College of Wisconsin	Withdrawn	No outcome recorded
Phase 4	NCT02886286 Background	May 2016 → Dec 2017	chronic pain syndrome	University Hospitals Cleveland Medical Center	Completed	No outcome recorded
Phase 4	NCT02727712 Background	Apr → Sep 2016	coronary artery disorder	Xiangya Hospital of Central South University	Unknown	No outcome recorded
Phase 4	NCT02621619 Background	Mar 2016 → Oct 2017	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 4	NCT02358850 Comparator	Jan 2016 → Jan 2019	neuropathy, painful	University of Nebraska	Terminated	No outcome recorded
Phase 4	NCT02546765 Comparator	Oct 2015 → May 2018	delirium	Beth Israel Deaconess Medical Center	Completed	No outcome recorded
Phase 4	NCT02459964 Comparator	Sep 2015 → Jun 2020	cancer of unknown primary site	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 4	NCT02449369 Background	Apr 2015 → Sep 2016	—	AdventHealth	Completed	No outcome recorded
Phase 4	NCT02483221 Comparator	Apr 2015 → Dec 2016	—	University of Erlangen-Nürnberg Medical School	Completed	No outcome recorded
Phase 4	NCT02222246 Comparator	Mar 2015 → May 2016	sickle cell disease	Duke University	Completed	No outcome recorded
Phase 4	NCT02389829 Comparator	Mar 2015 → Jun 2016	migraine disorder	Montefiore Medical Center	Completed	No outcome recorded
Phase 4	NCT01943565 Comparator	Dec 2014 → Jul 2016	—	Brigham and Women's Hospital	Terminated	No outcome recorded
Phase 4	NCT02219581 Background	Oct 2014 → Dec 2015	osteoarthritis	Thomas L Bradbury	Terminated	No outcome recorded
Phase 4	NCT02107339 Comparator	Mar 2014 → Jul 2016	—	Endeavor Health	Completed	No outcome recorded
Phase 4	NCT02110719 Comparator	Mar 2014 → Jul 2015	constipation disorder	Hartford Hospital	Completed	No outcome recorded
Phase 4	NCT02009722 Comparator	Jan → Dec 2014	—	Mayo Clinic	Completed	No outcome recorded
Phase 4	NCT02035709 Comparator	Dec 2013 → Apr 2015	—	University of Erlangen-Nürnberg Medical School	Completed	No outcome recorded
Phase 4	NCT02111746 Background	Nov 2013 → May 2017	—	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT02295124 Comparator	Aug 2012 → Jan 2016	—	University Health Network, Toronto	Completed	No outcome recorded
Phase 4	NCT02056301 Comparator	Aug 2012 → Apr 2019	pectus excavatum	Baylor College of Medicine	Terminated	No outcome recorded
Phase 4	NCT01490268 Comparator	Nov 2011 → Sep 2012	—	University of Erlangen-Nürnberg Medical School	Completed	No outcome recorded
Phase 4	NCT01546948 Comparator	Aug 2011 → Jun 2018	—	Endeavor Health	Completed	No outcome recorded
Phase 4	NCT01207596 Comparator	Sep 2010 → Sep 2011	neuropathy, painful	International Clinical Research Institute	Completed	No outcome recorded
Phase 4	NCT00955110 Background	Jun → Sep 2009	—	Endo USA Inc., a Keenova Therapeutics Company	Completed	No outcome recorded
Phase 4	NCT01591382 Comparator	Sep 2008 → Jun 2011	—	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 4	NCT00710086 Comparator	Jul 2008 → Sep 2009	—	Nanjing Medical University	Completed	No outcome recorded
Phase 4	NCT00385541 Comparator	Nov 2003 → Oct 2007	—	Columbia University	Completed	No outcome recorded

Phase not applicable24 trials
—	NCT06570577 Background	Feb 2025 → Mar 2027 expected	neuropathy, painful	Stony Brook University	Recruiting	No outcome recorded
—	NCT06015165 Background	Sep 2024 → Jun 2025 overdue	—	China-Japan Friendship Hospital	Recruiting	No outcome recorded
—	NCT04538573 Comparator	May 2022 → Aug 2023	—	St. Justine's Hospital	Unknown	No outcome recorded
—	NCT04613869 Background	Aug 2020 → Aug 2021	—	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
—	NCT03990038 Comparator	Aug → Oct 2019	—	Ciusss de L'Est de l'Île de Montréal	Terminated	No outcome recorded
—	NCT03715517 Comparator	Oct 2018 → Jul 2031 expected	liver cancer	University of Manitoba	Recruiting	No outcome recorded
—	NCT03471442 Background	May 2018 → Apr 2021	breast cancer	University of Alberta	Completed	No outcome recorded
—	NCT03458598 Background	Feb 2018 → Feb 2019	prostate neoplasm, substance-related disorder, urinary bladder neoplasm	University of Alberta	Completed	No outcome recorded
—	NCT03128346 Background	Oct 2017 → May 2018	—	Western University, Canada	Unknown	No outcome recorded
—	NCT02625181 Background	Jul 2016 → Nov 2017	—	Vanderbilt University	Completed	No outcome recorded
—	NCT02789410 Comparator	May 2016 → Sep 2017	obstetric disorder	Mayo Clinic	Completed	No outcome recorded
—	NCT02604589 Background	Mar → Nov 2016	—	Anthony Iacco	Terminated	No outcome recorded
—	NCT02501863 Background	Oct 2015 → Jul 2016	—	National Medical Center, Seoul	Completed	No outcome recorded
—	NCT02356198 Comparator	Mar 2015 → Oct 2017	—	Mayo Clinic	Completed	No outcome recorded
—	NCT02223377 Comparator	Jan 2015 → Mar 2019	—	McMaster University	Completed	No outcome recorded
—	NCT02192879 Comparator	Aug 2014 → May 2016	—	Duke University	Terminated	No outcome recorded
—	NCT02461056 Comparator	Jun → Jul 2014	breast cancer	Samsung Medical Center	Completed	No outcome recorded
—	NCT02164929 Comparator	Dec 2013 → Mar 2015	—	Duke University	Terminated	No outcome recorded
—	NCT01993238 Background	Nov 2013 → Jan 2014	—	Solta Medical	Completed	No outcome recorded
—	NCT01784991 Comparator	Dec 2011 → Apr 2014	—	Albert Einstein Healthcare Network	Terminated	No outcome recorded
—	NCT01172782 Comparator	Jul 2009 → Feb 2010	—	Korea University Anam Hospital	Completed	No outcome recorded
—	NCT02785055 Comparator	Apr 2009 → Feb 2014	—	Benaroya Research Institute	Completed	No outcome recorded
—	NCT00644111 Comparator	Feb 2008 → Jul 2011	—	University Health Network, Toronto	Completed	No outcome recorded
—	NCT00547664 Background	Jan 2008 → Dec 2009	—	HPC Healthcare, Inc.	Completed	No outcome recorded

Evidence & citations 45 cited values

Every value below carries the sentence it was read from. 249 sources stand behind the page.

Field	Value	Cited text
Known as	hydromorphone	“This was a human laboratory systematic examination of whether adding the FDA-approved cannabinoid dronabinol (Marinol; oral) to the FDA-approved opioid hydromorphone (Dilaudid;...” NCT02901275 ↗ 225 “The ice packs, Tylenol, and Toradol regimen consists of around-the-clock ice packs, around-the-clock oral acetaminophen, around-the-clock intravenous ketorolac, and intravenous...” PMID 31201808 ↗ Jun 2019 “Intraoperative analgesia using short-acting opioids (e.g., fentanyl and/or hydromorphone) administered at induction and throughout surgery according to clinician judgment and...” NCT07565870 ↗ “Standard of Care analgosedation of choice using propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam administered according to the...” NCT06429657 ↗ “The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose.” NCT03972397 ↗ “patients will be placed on a patient controlled analgesic (PCA) pump (hydromorphone: loading dose if needed; 5-6 mcg/kg continuous infusion; 5-6 mcg/kg six minute demand dose).” NCT00413582 ↗ “Participants (N = 21; 57% women; mean age = 63.4 ± 6.4 yr) with knee osteoarthritis received oral combinations of placebo, hydromorphone (2 mg), and dronabinol (10 mg).” PMID 41481837 ↗ Dec 2025 “Total IntraVenous Anesthesia - to achieve deep-sedation via chemical analgesic (propofol, dexmedetomidine, fentanyl, hydromorphone); continuous intravenous infusion.” NCT07672301 ↗ “PACU analgesia for both groups will be the usual care regime of fentanyl or hydromorphone bolus as prescribed by the physician anesthesiologist doing the case.” NCT05693675 ↗ “The patient-controlled anesthesia will be filled with morphine or hydromorphone. Pumps will be programmed be on demand only with no basal rate.” NCT03393117 ↗ “Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone.” NCT03471442 ↗ “PCA opioid will include morphine OR hydromorphone (if patient has a sensitivity or is unable to tolerate or allergic to morphine).” NCT06940570 ↗ “The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.” NCT04538573 ↗ “Intravenous hydromorphone PCA will be initiated postoperatively with dosing prescriptions made by the primary surgical team.” NCT02192879 ↗ “Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase.” NCT00803283 ↗ “Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex.” NCT00547664 ↗ “For Anes. Group, hydromorphone intravenous pump (PCIA) with 0.04mg/hr and 0.2mg/hr bolus controlled administration.” NCT06015165 ↗ “All groups will also receive bolus doses of opioids (IV morphine or hydromorphone) as needed for breakthrough pain.” NCT02546765 ↗ “Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID” NCT03990038 ↗ “A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.” NCT04566250 ↗ “Participants were administered an oral dose of the opioid hydromorphone (4mg) on day 2 of the study.” NCT02360371 ↗ “Participants will receive usual care with IV Fentanyl or hydromorphone per hospital protocols” NCT06110546 ↗ “Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone)” NCT03472469 ↗ “medications in the opioid family such as Hydromorphone, Hydrocodone, Tramadol, or Oxycodone.” NCT04176783 ↗ “Hydromorphone will be received intravenously using a patient controlled administration pump” NCT06559969 ↗ “Hydromorphone 0.04 mg/kg (maximum mg) by mouth 4 to 6 hours as needed, number 10 doses” NCT06671002 ↗ “* Hydromorphone 2 mg by mouth every four to six hours as needed for pain, 10 doses” NCT05722002 ↗ “Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)” NCT01993238 ↗ “Post-op anesthesia - Hydromorphone patient-controlled analgesia (PCA) 0.2 mg/8 min” NCT03448068 ↗ “Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over.” NCT02727712 ↗ “Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.” NCT01932554 ↗ “rescue analgesia with hydromorphone may be administered as clinically indicated.” NCT07588802 ↗ “Dexmedetomidine Combined With Hydromorphone in Tonsillectomy and Adenoidectomy” NCT03760809 ↗ “along with hydromorphone, oxycodone/acetaminophen, or a hydromorphone PCA” NCT03330119 ↗ “0.1% ropivicaine + 10 mcg/mL hydromorphone at 6 mL/hr continuous rate” NCT02423876 ↗ “2 mg IV hydromorphone administered over 2-3 minutes as initial dose” NCT01311895 ↗ “Examples of opioids are morphine and hydromorphone.” NCT04221165 ↗ “FDA-approved opioid hydromorphone (Dilaudid; oral)” NCT04036968 ↗ “The PCA drug will be Dilaudid (hydromorphone).” NCT02111746 ↗ “as well as opioids (morphine, hydromorphone).” NCT04291599 ↗ “Intravenous Challenge Drug: Hydromorphone” NCT03389750 ↗ “Hydromorphone 1mg PO q4-6h PRN” NCT04044820 ↗ “Hydromorphone extended release” NCT04132011 ↗ “IV-PCA with hydromorphone” NCT02501863 ↗ “Intravenous hydromorphone” NCT06570577 ↗ “Hydromorphone (Dilaudid®)” NCT06240390 ↗ “Hydromorphone 2mg” NCT06495632 ↗ “Hydromorphone” NCT00822614 ↗ “Hydromorphone” NCT02886286 ↗ NCT00365898 ↗ NCT01447212 ↗ NCT04258631 ↗ NCT03300674 ↗ NCT03478423 ↗ NCT04296305 ↗ NCT02277782 ↗ NCT06406400 ↗ NCT00411164 ↗ NCT02483221 ↗ NCT00399048 ↗ NCT01598545 ↗ NCT03282669 ↗ NCT02621619 ↗ NCT04396587 ↗ NCT00411307 ↗ NCT03933397 ↗ NCT06669650 ↗ NCT01675778 ↗ NCT00600158 ↗ NCT02987920 ↗ NCT00644111 ↗ NCT00710086 ↗ NCT01598506 ↗ NCT06320041 ↗ NCT07489625 ↗ NCT00125801 ↗ NCT05708521 ↗ NCT00158236 ↗ NCT03107481 ↗ NCT00398957 ↗ NCT01943565 ↗ NCT00853554 ↗ NCT03715517 ↗ NCT01892709 ↗ NCT00398788 ↗ NCT02880800 ↗ NCT02789410 ↗ NCT00305110 ↗ NCT01642030 ↗ NCT03564548 ↗ NCT01207596 ↗ NCT03726268 ↗ NCT00627367 ↗ NCT03648008 ↗ NCT03521102 ↗ NCT00261495 ↗ NCT03933865 ↗ NCT00399295 ↗ NCT04230681 ↗ NCT07430345 ↗ NCT00411268 ↗ NCT03115151 ↗ NCT05848635 ↗ NCT00305058 ↗ NCT05610072 ↗ NCT00410540 ↗ NCT04300231 ↗ NCT06868589 ↗ NCT04111328 ↗ NCT06576830 ↗ NCT01490268 ↗ NCT00465647 ↗ NCT00411034 ↗ NCT00499746 ↗ NCT01172782 ↗ NCT03375515 ↗ NCT03893734 ↗ NCT02449369 ↗ NCT06784180 ↗ NCT00474110 ↗ NCT01824524 ↗ NCT01123486 ↗ NCT02222246 ↗ NCT05565495 ↗ NCT05244226 ↗ NCT04429022 ↗ NCT00682435 ↗ NCT02785055 ↗ NCT00955110 ↗ NCT01218984 ↗ NCT06575699 ↗ NCT04785768 ↗ NCT01648699 ↗ NCT03768024 ↗ NCT06823180 ↗ NCT07315022 ↗ NCT05579223 ↗ NCT03088306 ↗ NCT05375916 ↗ NCT02459964 ↗ NCT02939209 ↗ NCT03767933 ↗ NCT02389829 ↗ NCT02164929 ↗ NCT06218160 ↗ NCT00980798 ↗ NCT05901441 ↗ NCT00410878 ↗ NCT04436224 ↗ NCT03619785 ↗ NCT02044094 ↗ NCT05842044 ↗ NCT02107339 ↗ NCT01812759 ↗ NCT02035709 ↗ NCT02056301 ↗ NCT00631319 ↗ NCT02356198 ↗ NCT07224620 ↗ NCT06785571 ↗ NCT06525740 ↗ NCT02295124 ↗ NCT06617949 ↗ NCT00195910 ↗ NCT02096003 ↗ NCT02062879 ↗ NCT02084355 ↗ NCT02461056 ↗ NCT02205983 ↗ NCT03789318 ↗ NCT00003115 ↗ NCT02321319 ↗ NCT02787928 ↗ NCT02358850 ↗ NCT01006356 ↗ NCT03151434 ↗ NCT03104816 ↗ NCT02789969 ↗ NCT06205199 ↗ NCT04243954 ↗ NCT02223377 ↗ NCT01621100 ↗ NCT00825370 ↗ NCT02437669 ↗ NCT02372591 ↗ NCT00385541 ↗ NCT01429298 ↗ NCT06411795 ↗ NCT04234191 ↗ NCT01487512 ↗ NCT01487564 ↗ NCT00410943 ↗ NCT01866254 ↗ NCT01429285 ↗ NCT06949059 ↗ NCT03592992 ↗ NCT02601027 ↗ NCT03579446 ↗ NCT06962306 ↗ NCT04398316 ↗ NCT01784991 ↗ NCT03757559 ↗ NCT00549042 ↗ NCT01709747 ↗ NCT01591382 ↗ NCT05576675 ↗ NCT03309163 ↗ NCT05552443 ↗ NCT01205126 ↗ NCT00410644 ↗ NCT01546948 ↗ NCT04081376 ↗ NCT00766831 ↗ NCT03541759 ↗ NCT00410787 ↗ NCT02067520 ↗ NCT00177060 ↗ NCT03553498 ↗ NCT02625181 ↗ NCT02009722 ↗ NCT06036797 ↗ NCT05027919 ↗ NCT00992576 ↗ NCT04613869 ↗ NCT00410748 ↗ NCT04752033 ↗
Known as	Dilaudid	“This was a human laboratory systematic examination of whether adding the FDA-approved cannabinoid dronabinol (Marinol; oral) to the FDA-approved opioid hydromorphone (Dilaudid;...” NCT02901275 ↗ 18 “The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose.” NCT03972397 ↗ “Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex.” NCT00547664 ↗ “Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.” NCT01447888 ↗ “Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.” NCT03458598 ↗ “Dilaudid SR Tablets and Immediate Release Dilaudid Tablets (Hydromorphone HCI)” NCT00410943 ↗ “If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid” NCT02219581 ↗ “Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.” NCT03052816 ↗ “injectable hydromorphone (HDM; trade name Dilaudid™)” NCT01447212 ↗ “FDA-approved opioid hydromorphone (Dilaudid; oral)” NCT04036968 ↗ “The PCA drug will be Dilaudid (hydromorphone).” NCT02111746 ↗ “IV Dilaudid 1mg q3h for breakthrough pain” NCT05231460 ↗ “Hydromorphone (Dilaudid®)” NCT06240390 ↗ “Dilaudid” NCT02785003 ↗ NCT01986946 ↗ NCT04240626 ↗ NCT02958566 ↗ NCT01442818 ↗ NCT02110719 ↗
Known as	Dilaudid CR	“An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)” NCT00399048 ↗ 1 “Dilaudid CR (Hydromorphone HCI)” NCT00411268 ↗
Known as	Dilaudid CR (controlled release)	“A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain” NCT00398788 ↗
Known as	Dilaudid Injectable Product	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03987022 ↗
Known as	Dilaudid OROS	“Dilaudid OROS 16mg (Dilaudid Slow Release; hydromorphone HCL)” NCT00399295 ↗
Known as	Dilaudid Slow Release	“Dilaudid OROS 16mg (Dilaudid Slow Release; hydromorphone HCL)” NCT00399295 ↗
Known as	Dilaudid SR	“A Repeated-Dose Evaluation of Analgesic Use and Safety of Dilaudid SR( Hydromorphone HCI) in Patients With Chronic Cancer Pain” NCT00411034 ↗ 1 “Safety and Tolerability of Long-Term Administration of Dilaudid SR (Hydromorphone HCI) in Cancer Pain” NCT00410787 ↗
Known as	Dilaudid SR Tablets	“A Repeated-Dose Pharmacokinetic Evaluation of Dilaudid SR Tablets (Hydromorphone HCI) in Patients With Chronic Pain” NCT00410878 ↗ 1 “Dilaudid SR Tablets and Immediate Release Dilaudid Tablets (Hydromorphone HCI)” NCT00410943 ↗
Known as	Dilaudid-hp	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Known as	Dimorphone	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Known as	Exalgo	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Known as	HDM	“injectable hydromorphone (HDM; trade name Dilaudid™)” NCT01447212 ↗
Known as	Hidromorfona	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Known as	Hydromorph Contin	“Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID” NCT03990038 ↗
Known as	Hydromorphon	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Known as	hydromorphone ER	“OBJECTIVE: This multicenter, double-blind, placebo-controlled study using a randomized withdrawal design evaluated the efficacy and safety of once-daily OROS hydromorphone ER...” PMID 20429852 ↗ Jun 2010
Known as	Hydromorphone HCI	“A Randomized, Repeated- Dose, Parallel-Group Comparison of Safety, Efficacy, and Quality of Life Measures With Dilaudid CR (Hydromorphone HCI) or Oxycontin (Oxycodone HCI) in...” NCT00399048 ↗ 3 “OROS Hydromorphone HCI (slow release)” NCT00410878 ↗ “appropriate dose of hydromorphone HCI” NCT00410943 ↗ “OROS Hydromorphone HCI (slow release)” NCT00411034 ↗
Known as	Hydromorphone HCl	“A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain” NCT00398788 ↗ 3 “Hydromorphone Hcl 4 milligram (mg) Tab 2 times after surgery as basic medication.” NCT03541759 ↗ “Hydromorphone HCl OROS 8 milligram (mg) once daily for 2 weeks.” NCT01006356 ↗ “Dilaudid OROS 16mg (Dilaudid Slow Release; hydromorphone HCL)” NCT00399295 ↗
Known as	Hydromorphone Hydrochloride	“Drug: Hydromorphone Hydrochloride Hydromorphone hydrochloride injection is used for perioperative lung tumor ablation” NCT05848635 ↗ 6 “Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS)” NCT01006356 ↗ “hydromorphone hydrochloride 4 milligrams” NCT03757559 ↗ NCT03128346 ↗ NCT03214510 ↗ NCT02604589 ↗ NCT01709721 ↗
Known as	Hydromorphone hydrochloride cii	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Known as	Hydromorphone Hydrochloride Injection	“Experimental Drug: Hydromorphone Hydrochloride Injection.” NCT05579223 ↗
Known as	HYDROMORPHONE SULFATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Known as	IDS-NH-004	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Known as	IVH	“OBJECTIVE: Intranasal fentanyl (INF) quickly and noninvasively relieves severe pain, whereas intravenous hydromorphone (IVH) reliably treats severe cancer pain but requires...” PMID 32649717 ↗ Jul 2020
Known as	Jurnista	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Known as	N02AA03	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Known as	NMED-1077	“This study will test an experimental drug called OROS® hydromorphone hydrochloride (HCl) (NMED-1077), a once daily opioid analgesic that can relieve pain.” NCT00549042 ↗
Known as	Novolaudon	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Known as	NSC-117862	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Known as	NSC-19046	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Known as	OROS hydromorphone	“The purpose of this study is to investigate the pharmacokinetics of OROS hydromorphone in healthy adult Taiwanese participants after the oral administration of a single 16 mg dose.” NCT01487564 ↗ 5 “This study will test an experimental drug called OROS® hydromorphone hydrochloride (HCl) (NMED-1077), a once daily opioid analgesic that can relieve pain.” NCT00549042 ↗ “OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg” NCT00631319 ↗ “The equianalgesic doses were 16 mg OROS hydromorphone and 40 mg SR oxycodone (median values).” PMID 20384968 ↗ Sep 2010 “OROS hydromorphone HCl 4 to 32 mg taken orally once daily for 16 weeks” NCT00980798 ↗ “16 mg OROS hydromorphone under fasting conditions” PMID 17270055 ↗ Feb 2007
Known as	OROS hydromorphone (slow release)	“OROS hydromorphone (slow release) 8 mg and 16 mg tablets and placebo taken orally once daily” NCT00411164 ↗ 1 “OROS hydromorphone (slow release) in patients with chronic cancer pain” NCT00410787 ↗
Known as	OROS hydromorphone ER	“OBJECTIVE: This multicenter, double-blind, placebo-controlled study using a randomized withdrawal design evaluated the efficacy and safety of once-daily OROS hydromorphone ER...” PMID 20429852 ↗ Jun 2010
Known as	OROS Hydromorphone HCI	“OROS Hydromorphone HCI (slow release)” NCT00411034 ↗
Known as	OROS hydromorphone HCI (slow release)	“At the end of the washout period, all patients received OROS hydromorphone HCI (slow release) 8 mg or matching placebo to be taken once daily.” NCT00411164 ↗ 2 “OROS hydromorphone HCI (slow release) tablets in 8, 16, 32 and 64mg doses administered orally every 24 hours” NCT00410787 ↗ “OROS Hydromorphone HCI (slow release)” NCT00410878 ↗
Known as	OROS Hydromorphone HCI SR (slow release)	“OROS Hydromorphone HCI SR (slow release)” NCT00410943 ↗
Known as	OROS hydromorphone HCL	“This was a multicenter, open-label, randomized (patients are assigned different treatments based on chance), dose-titration, parallel-group study characterizing the...” NCT00399048 ↗ 2 “OROS hydromorphone HCl 4 to 32 mg taken orally once daily for 16 weeks” NCT00980798 ↗ “OROS hydromorphone HCL slow release 8, 16, 32, and 64mg tablets” NCT00410540 ↗
Known as	OROS hydromorphone hydrochloride (HCl)	“This study will test an experimental drug called OROS® hydromorphone hydrochloride (HCl) (NMED-1077), a once daily opioid analgesic that can relieve pain.” NCT00549042 ↗ 1 “Oral Osmotic Therapeutic System (OROS) hydromorphone hydrochloride (HCl) with controlled-release oxycodone HCl in participants with cancer-related pain.” NCT01205126 ↗
Known as	Palladone	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Known as	Palladone-sr	ChEMBL registry synonym — accepted as the source's own label CHEMBL398707 ↗
Action	Activate	“as well as intramuscular hydromorphone as an opioid agonist control (2, 4 mg) and placebo” PMID 10928310 ↗ Mar 2000 1 “Mu opioid receptor agonist” CHEMBL398707 ↗
Modality	Other / unclassified	“both opioids” PMID 40493496 ↗ Jun 2025
Route	Other	“hydromorphone bolus injection through an epidural catheter” NCT00003115 ↗
Target	OPRM1	“Mu opioid receptor agonist” CHEMBL398707 ↗